0001235802-20-000137.txt : 20201119
0001235802-20-000137.hdr.sgml : 20201119
20201119180218
ACCESSION NUMBER: 0001235802-20-000137
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20201117
FILED AS OF DATE: 20201119
DATE AS OF CHANGE: 20201119
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Orbimed ROF II LLC
CENTRAL INDEX KEY: 0001767936
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-34951
FILM NUMBER: 201329902
BUSINESS ADDRESS:
STREET 1: 601 LEXINGTON AVE., 54TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10022
BUSINESS PHONE: (212) 739-6400
MAIL ADDRESS:
STREET 1: 601 LEXINGTON AVE., 54TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10022
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: ORBIMED ADVISORS LLC
CENTRAL INDEX KEY: 0001055951
STATE OF INCORPORATION: DE
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-34951
FILM NUMBER: 201329903
BUSINESS ADDRESS:
STREET 1: 601 LEXINGTON AVENUE
STREET 2: 54TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10022
BUSINESS PHONE: (212) 739-6400
MAIL ADDRESS:
STREET 1: 601 LEXINGTON AVENUE
STREET 2: 54TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10022
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Xtant Medical Holdings, Inc.
CENTRAL INDEX KEY: 0001453593
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 205313323
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 664 CRUISER LANE
CITY: BELGRADE
STATE: MT
ZIP: 59714
BUSINESS PHONE: 406-388-0480
MAIL ADDRESS:
STREET 1: 664 CRUISER LANE
CITY: BELGRADE
STATE: MT
ZIP: 59714
FORMER COMPANY:
FORMER CONFORMED NAME: Bacterin International Holdings, Inc.
DATE OF NAME CHANGE: 20100615
FORMER COMPANY:
FORMER CONFORMED NAME: K KITZ INC
DATE OF NAME CHANGE: 20090108
4
1
primary_doc.xml
PRIMARY DOCUMENT
X0306
4
2020-11-17
0
0001453593
Xtant Medical Holdings, Inc.
XTNT
0001055951
ORBIMED ADVISORS LLC
601 LEXINGTON AVENUE
54TH FLOOR
NEW YORK
NY
10022
1
0
1
0
0001767936
Orbimed ROF II LLC
601 LEXINGTON AVE., 54TH FLOOR
NEW YORK
NY
10022
1
0
1
0
Common Stock
2020-11-17
4
X
0
765992
0.01
A
53468376
I
See Footnotes
Common Stock
2020-11-17
4
X
0
765992
0.01
A
54234368
I
See Footnotes
Common Stock
2020-11-17
4
X
0
1531984
0.01
A
55766352
I
See Footnotes
Common Stock
2020-11-17
4
X
0
434008
0.01
A
15734696
I
See Footnotes
Common Stock
2020-11-17
4
X
0
434008
0.01
A
16168704
I
See Footnotes
Common Stock
2020-11-17
4
X
0
868016
0.01
A
17036720
I
See Footnotes
Common Stock
70423
I
See Footnotes
Common Stock
70423
I
See Footnotes
Warrant (right to buy)
0.01
2020-11-17
4
X
0
765992
0
D
2018-09-17
2028-08-01
Common Stock
765992
0
I
See Footnotes
Warrant (right to buy)
0.01
2020-11-17
4
X
0
434008
0
D
2018-09-17
2028-08-01
Common Stock
434008
0
I
See Footnotes
Warrant (right to buy)
0.01
2020-11-17
4
X
0
765992
0
D
2019-04-11
2029-04-01
Common Stock
765992
0
I
See Footnotes
Warrant (right to buy)
0.01
2020-11-17
4
X
0
434008
0
D
2019-04-11
2029-04-01
Common Stock
434008
0
I
See Footnotes
Warrant (right to buy)
0.01
2020-11-17
4
X
0
1531984
0
D
2020-11-06
2030-05-06
Common Stock
1531984
0
I
See Footnotes
Warrant (right to buy)
0.01
2020-11-17
4
X
0
868016
0
D
2020-11-06
2030-05-06
Common Stock
868016
0
I
See Footnotes
These securities are held of record by ROS Acquisition Offshore LP ("ROS Acquisition"). OrbiMed Advisors LLC ("Advisors"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the investment manager of ROS Acquisition. Advisors is also the investment manager of Royalty Opportunities S.a r.l., of which ROS Acquisition is a wholly-owned subsidiary. By virtue of such relationships, Advisors may be deemed to have voting and investment power with respect to the securities held by ROS Acquisition noted above and as a result may be deemed to have beneficial ownership over such securities. Advisors exercises its investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the securities held by ROS Acquisition.
This report on Form 4 is jointly filed by Advisors and OrbiMed ROF II LLC ("ROF II"). Each of Advisors, ROF II, ROS Acquisition and OrbiMed Royalty Opportunities II, LP ("ORO II") disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. Advisors has designated certain representatives, including Matthew Rizzo and Michael Eggenberg, both of whom are employees of Advisors, to serve on the Company's board of directors. This report shall not be deemed an admission that any such entity is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act or for any other purposes.
These securities are held of record by ORO II. ROF II is the general partner of ORO II, and Advisors is the managing member of ROF II. By virtue of such relationships, Advisors may be deemed to have voting and investment power with respect to the securities held by ORO II noted above and as a result may be deemed to have beneficial ownership over such securities. Advisors exercises its investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the securities held by ORO II.
This restricted stock unit award was granted to Michael Eggenberg, a director of the Company who is an employee of Advisors, who was designated by Advisors to sit on the Company's board of directors. Upon vesting of the restricted stock unit award, ownership of the shares underlying the restricted stock unit award will be transferred to ROS Acquisition and ORO II.
This restricted stock unit award was granted to Matthew Rizzo, a director of the Company who is an employee of Advisors, who was designated by Advisors to sit on the Company's board of directors. Upon vesting of the restricted stock unit award, ownership of the shares underlying the restricted stock unit award will be transferred to ROS Acquisition and ORO II.
/s/ Sven H. Borho, Member of OrbiMed Advisors LLC
2020-11-19
/s/ Sven H. Borho, Member of OrbiMed ROF II LLC
2020-11-19
/s/ Carl L. Gordon, Member of OrbiMed Advisors LLC
2020-11-19
/s/ Carl L. Gordon, Member of OrbiMed ROF II LLC
2020-11-19
/s/ Jonathan T. Silverstein, Member of OrbiMed Advisors LLC
2020-11-19
/s/ Jonathan T. Silverstein, Member of OrbiMed ROF II LLC
2020-11-19